Brain FDG PET-MR Closely Tracks PET/CT, But Scan Timing Changes the Numbers
In a head-to-head clinical comparison, [18F]FDG brain PET-MR mirrored PET/CT with striking consistency, even as the two scans produced systematically different absolute uptake values. The cohort included patients referred for refractory epilepsy or cognitive problems, making the findings directly relevant to the kind of neurologic workups where metabolic imaging is used to localize dysfunction and guide care. Fifty-five image pairs survived quality control, enough to support a quantitative comparison within the same individuals rather than a loose cross-sectional snapshot.
The central message is simple and clinically useful. The two modalities agreed closely on where the brain was metabolically active, but not on the exact magnitude of uptake.
PET/CT was performed at about 30 minutes after tracer injection, while PET-MR followed at about 100 minutes. That difference is not a technical footnote; it is the main reason the numbers diverged. FDG continues to redistribute and clear over time, and by the later scan the tracer has had a different chance to settle across gray and white matter compartments. In practice, this means PET-MR can still be highly interpretable, but its SUVs cannot be treated as interchangeable with those from an earlier PET/CT acquisition.
Quantitative Agreement Was Strong Within Patients
The strongest evidence of concordance came from within-subject comparisons. Correlations between modalities were very high overall at 0.96, with a range from 0.84 to 0.99. Across regions and participants, correlations remained solid at 0.82, ranging from 0.72 to 0.90. Those values matter because they suggest that the same underlying metabolic pattern is being detected even when the scanner platform and acquisition approach differ.
A 20% average increase in PET-MR SUVs is a meaningful shift, not random noise. Higher-uptake regions showed the largest difference, which fits with the expectation that later imaging can amplify contrast between metabolically active cortex and surrounding tissue. For clinicians reading scans, the implication is straightforward: PET-MR may preserve the diagnostic map while changing the numeric scale.
Gray-White Matter Contrast Favored PET-MR
Voxel-wise analysis gave the comparison a sharper anatomical edge. PET-MR showed relatively higher uptake in the visual and auditory cortices, lower uptake in medial frontal and anteromesial temporal cortices, and better gray-white matter contrast overall. In brain FDG imaging, contrast is often the practical currency of interpretation. Better separation between cortical and subcortical tissue can make abnormal patterns easier to recognize, especially in epilepsy evaluations where subtle asymmetry or focal hypometabolism carries diagnostic weight.
One line from the data stands out on its own: PET-MR produced better gray-white matter contrast.
That finding is not just cosmetic. In neurologic imaging, contrast can determine whether a region appears borderline abnormal or clearly affected. The later scan timing likely contributes to the sharper separation, because metabolic background has shifted by the time PET-MR is acquired. Sensory activation between scans may also have influenced uptake in cortical areas, especially visual and auditory cortex, where environmental stimulation can leave a measurable footprint on FDG distribution.
Why the Differences Make Physiologic Sense
The biological explanation fits the acquisition strategy. FDG uptake reflects glucose metabolism, but the signal is sensitive to timing, local neuronal activity, and the attenuation correction method used during reconstruction. PET/CT and PET-MR each rely on different attenuation correction approaches, and the study’s close overall correspondence suggests those technical differences did not distort the core metabolic pattern. Instead, the larger driver of divergence was the interval between scans.
Later imaging can favor higher measured SUVs because the tracer has had more time to evolve in tissue compartments, while some regions may appear relatively reduced if their activity has already peaked or if background has fallen. The cortical regions with higher uptake on PET-MR likely reflect this combination of later timing and ongoing tissue-specific tracer kinetics. The lower uptake in medial frontal and anteromesial temporal cortices may reflect the same temporal shift, rather than a true biological reversal between scans.
Clinical Use Depends on Knowing What Is Comparable
For neurologists and nuclear medicine teams, the practical question is not whether the two modalities are identical. They are not. The useful question is whether PET-MR can be trusted to preserve the clinically relevant pattern of brain FDG uptake. In this cohort, the answer was yes, provided that readers understand the acquisition differences and interpret absolute SUV values in context.
That matters in epilepsy and cognitive evaluations, where imaging often informs lesion localization, lateralization, or broader assessment of network dysfunction. A modality that keeps the same regional ordering while changing absolute values can still be clinically valuable, but only if institutions avoid comparing raw SUVs across protocols as though they were interchangeable. A later PET-MR scan may also offer the anatomical advantages of simultaneous MR imaging, which can improve structural correlation when metabolic abnormalities are subtle.
This is also a reminder that quantitative brain PET is not detached from the environment in which it is acquired. Timing, stimulation, and reconstruction all shape the final image. The high level of agreement seen here supports continued clinical use of brain PET-MR, but only when readers respect the fact that PET-MR and PET/CT are similar tools with different measurement conditions.
What This Cohort Does and Does Not Answer
The study was limited to 55 quality-controlled image pairs, so the numerical estimates should be viewed as informative rather than definitive for every neurologic scenario. It also compared scans acquired at different times after injection, which helps explain the observed differences but prevents a pure platform-only comparison. Even so, the data are strong enough to support a clear operational conclusion: brain PET-MR can serve clinical practice reliably when the timing-driven shift in SUVs is recognized.
The remaining question is not whether PET-MR can reproduce PET/CT patterns. It can. The more important issue is how individual centers should standardize uptake timing and interpret quantitative thresholds when the goal is longitudinal follow-up or cross-platform comparison.